DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
1783,Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B,Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial,DIABETES.OBES.METAB,2018,20,5.0,1111~1120,,VERTIS FACTORIAL,NCT02099110;EudraCT2013-003698-82,T2D;Obesity,Parallel,US;CA;AR;CO;MX;CZ;HU;IL;PL;RO;RU;SK;UA;MY;PH;NZ;BG;IT;FI;TH;CL,Phase 3,0.0,Double-Blind Extension,True,sitagliptin,DPP4,100,MG/DAY,ORAL,QD,TAB,1233,247.0,247,,Treated,Constrained Longitudinal Data Analysis,,52.0,WK,HbA1c,Mean,8.5,percent,1.0,SD,,,LS Mean,-0.8,percent,,95%CI,-1.0,-0.7,LS Mean,7.78,percent,,,,,LS Mean,-9.324,,,,,62.348,54.8,YR
1783,Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B,Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial,DIABETES.OBES.METAB,2018,20,5.0,1111~1120,,VERTIS FACTORIAL,NCT02099110;EudraCT2013-003698-82,T2D;Obesity,Parallel,US;CA;AR;CO;MX;CZ;HU;IL;PL;RO;RU;SK;UA;MY;PH;NZ;BG;IT;FI;TH;CL,Phase 3,1.0,Double-Blind Extension,True,ertugliflozin,SGLT2,5,MG/DAY,ORAL,QD,TAB,1233,250.0,250,,Treated,Constrained Longitudinal Data Analysis,,52.0,WK,HbA1c,Mean,8.6,percent,1.0,SD,,,LS Mean,-1.0,percent,,95%CI,-1.1,-0.8,LS Mean,7.58,percent,,,,,LS Mean,-11.655,,,,,50.8,55.1,YR
1783,Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B,Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial,DIABETES.OBES.METAB,2018,20,5.0,1111~1120,,VERTIS FACTORIAL,NCT02099110;EudraCT2013-003698-82,T2D;Obesity,Parallel,US;CA;AR;CO;MX;CZ;HU;IL;PL;RO;RU;SK;UA;MY;PH;NZ;BG;IT;FI;TH;CL,Phase 3,2.0,Double-Blind Extension,True,ertugliflozin,SGLT2,15,MG/DAY,ORAL,QD,TAB,1233,248.0,248,,Treated,Constrained Longitudinal Data Analysis,,52.0,WK,HbA1c,Mean,8.6,percent,1.0,SD,,,LS Mean,-0.9,percent,,95%CI,-1.1,-0.8,LS Mean,7.68,percent,,,,,LS Mean,-10.49,,,,,54.032,55.3,YR
1783,Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B,Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial,DIABETES.OBES.METAB,2018,20,5.0,1111~1120,,VERTIS FACTORIAL,NCT02099110;EudraCT2013-003698-82,T2D;Obesity,Parallel,US;CA;AR;CO;MX;CZ;HU;IL;PL;RO;RU;SK;UA;MY;PH;NZ;BG;IT;FI;TH;CL,Phase 3,3.0,Double-Blind Extension,True,ertugliflozin;sitagliptin,SGLT2;DPP4,5;100,MG/DAY;MG/DAY,ORAL,QD;QD,TAB;TAB,1233,243.0,243,,Treated,Constrained Longitudinal Data Analysis,,52.0,WK,HbA1c,Mean,8.6,percent,1.0,SD,,,LS Mean,-1.4,percent,,95%CI,-1.5,-1.2,LS Mean,7.18,percent,,,,,LS Mean,-16.317,,,,,50.617,55.2,YR
1783,Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B,Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial,DIABETES.OBES.METAB,2018,20,5.0,1111~1120,,VERTIS FACTORIAL,NCT02099110;EudraCT2013-003698-82,T2D;Obesity,Parallel,US;CA;AR;CO;MX;CZ;HU;IL;PL;RO;RU;SK;UA;MY;PH;NZ;BG;IT;FI;TH;CL,Phase 3,4.0,Double-Blind Extension,True,ertugliflozin;sitagliptin,SGLT2;DPP4,15;100,MG/DAY;MG/DAY,ORAL,QD;QD,TAB;TAB,1233,244.0,244,,Treated,Constrained Longitudinal Data Analysis,,52.0,WK,HbA1c,Mean,8.6,percent,1.0,SD,,,LS Mean,-1.4,percent,,95%CI,-1.5,-1.3,LS Mean,7.18,percent,,,,,LS Mean,-16.317,,,,,51.639,55.1,YR
